precisionHEOR, Los Angeles, CA, USA.
Novo Nordisk Inc., Plainsboro, NJ, USA.
Inquiry. 2021 Jan-Dec;58:46958021990516. doi: 10.1177/0046958021990516.
While substantial public health investment in anti-smoking initiatives has had demonstrated benefits on health and fiscal outcomes, similar investment in reducing obesity has not been undertaken, despite the substantial burden obesity places on society. Anti-obesity medications (AOMs) are poorly prescribed despite evidence that weight loss is not sustained using other strategies alone.We used a simulation model to estimate the potential impact of 100% uptake of AOMs on Medicare and Medicaid spending, disability payments, and taxes collected relative to status quo with negligible AOM use. Relative to status quo, AOM use simulation would result in Medicare and Medicaid savings of $231.5 billion and $188.8 billion respectively over 75 years. Government tax revenues would increase by $452.8 billion. Overall, the net benefit would be $746.6 billion. Anti-smoking efforts have had substantial benefits for society. A similar investment in obesity reduction, including broad use of AOMs, should be considered.
尽管在反吸烟行动方面进行了大量的公共卫生投资，这些投资已经在健康和财政结果方面显示出了明显的益处，但在减少肥胖方面却没有进行类似的投资，尽管肥胖给社会带来了巨大的负担。尽管有证据表明，仅通过其他策略无法维持体重减轻，但抗肥胖药物（AOM）的处方却很差。我们使用模拟模型来估计 100%使用 AOM 对医疗保险和医疗补助支出、残疾支付和税收的潜在影响，与几乎不使用 AOM 的现状相比。与现状相比，AOM 使用模拟将导致医疗保险和医疗补助在 75 年内分别节省 2315 亿美元和 1888 亿美元。政府税收收入将增加 4528 亿美元。总体而言，净收益将达到 7466 亿美元。反吸烟行动已经给社会带来了巨大的好处。应该考虑在减少肥胖方面进行类似的投资，包括广泛使用 AOM。
